Congenital DM1: what to expect and management tips
Disclosure statement

- Involved in clinical trial activity with Biogen and Isis for SMA
- Have consultation agreements in the past with GSK, Acceleron and Shire
- Sit on PTC Therapeutics Advisory Board (volunteer)
Walk through the life of a child with congenital DM1 and pick out some of the more significant issues

Learning from each other

Data from studies we have conducted with Dr. Johnson, Utah
What is the definition of CDM?

Prognosis by duration?

Autistic features

Sleep Myotonia GI, etc.

Birth

Diagnosis

ventilation

Development

Supportive management
What is the definition of CDM?

Diagnosis

Prognosis by duration?

Development

Autistic features

Supportive management

Sleep, Myotonia, GI, etc

Birth

• Pregnancy
• Planning

Decision Making
Are we giving the best advice and opportunity to discuss family planning?
Approximately half the time the child is the index ‘case’ for the family
Birth

Pregnancy and Planning

- Maternal age 22-37 years
- 59% the neonate was the index case for the family
- 79% offered genetic counseling after the birth of their CDM child
- 79% said they had enough knowledge of CDM to make educated decisions about future pregnancies
- No one in the study actually had prenatal testing for the reported cases

Mothers who knew they had DM1
- 15-35 years old at diagnosis
- 50% had counseling to explain risk of CDM
- 50% had prenatal testing offered
- No one chose to have prenatal testing
- 50% said now that they had a child with DM1 they would decide not to have another child
- 25% would have more children, and 25% undecided

Mothers who did not know they had DM1
- 60% said they would have another child
- 30% no more children
- 10% undecided
- For the mothers who would have another child all said they would have prenatal testing for future pregnancies
There is no uniform definition of congenital DM1
  • Hypotonia only vs. severe
  • Family history
  • Cut off birth, 1 year?

Childhood/juvenile/early onset definition also problematic
  • Why cut off at 10yo?
What is the definition of CDM?

- Hard to prognosticate and inform parents without a clear definition
- Difficult for science and study
- Not physiologically important
Any newly diagnosed child up to age 3 years meeting the following criteria:

1. Has symptoms in the neonatal period causing death or admission to hospital for greater than 72 hours related to DM1
2. Has a genetically confirmed diagnosis of DM1 in child (or mother)
3. Repeat size >200

All others are childhood or pediatric DM1
Birth Duration and Prognosis

Ventilation Days of ventilation

Ventilated 162 days

Respiratory support for 1643 days

Ventilated 1643 days

Ventilated for 1643 days

Still ventilated at 1643 days

Ventilated 162 days

CTG repeat size and ventilation duration
Birth Duration and Prognosis

Ventilation Days of ventilation

Ventilated 1643 days

Ventilated for 1643 days

CTG repeat size and ventilation duration
Children identified
N=23

Not assigned to group
3 children
(see text)

Group

No ventilation
N=4

Ventilation < 30d
N=8

Ventilation > 30 d
N=8

1st year mortality

No deaths

No deaths

2 deaths
(age 8 m and 10m)

Follow-up mortality

1 death
(age 1y9m)

No deaths

No deaths

1 death
(age 11 years)

Lost to follow-up

No children

1 child

No children

Age at follow-up

3y-16 y

2y-16y

5y-13y
CDM1 is a disorder of muscle immaturity

There is still a prevailing sense that ventilation beyond 30 days is futile

There are many complications that can occur in the neonatal period that impact breathing and feeding

Long term ventilation is a care challenge

Families should be given the proper information
6 minute walk time by age

Differences of six minutes walk between CDM and Control groups
Autism issue

- Facial movement reduced
- Recognition of facial expression impaired
- Anxiety
- Cognitive and language disability
- Typically patients score clinically significant scores on traditional autism scales

Do patients have autism or are there unique features of childhood DM1 that makes it appear so?
ASSQ and IQ with age
Quality of life in older cohort

PEDS QL for CDM patients

- Total
- 95% Confidence Limits
- Regression
- Sleep
- Myotonia
- Cardiac
- Gastrointestinal
- Ophthalmology
- Orthopedic
Medical Management and Monitoring

- **Sleep**
  - Excessive sleep often stated as a problem in clinic
  - RCT’s of modafinil to treat hypersomnolence showed mixed results: improvement on sleep scale but not necessarily on activity level (adults)
  - No randomized trial of methylphenidate
## Medical Management and Monitoring

<table>
<thead>
<tr>
<th>US Registry</th>
<th>Never</th>
<th>Slight chance</th>
<th>Moderate chance</th>
<th>High chance</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitting and reading</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Watching tv</td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Sitting inactive in a public place</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>As a passenger in car for an hour without break</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Lying down in the afternoon for a nap</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Sitting and talking to someone</td>
<td>9</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Sitting quietly after lunch without alcohol</td>
<td>7</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>In a car while stopped a few minutes in traffic</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>11</td>
</tr>
</tbody>
</table>
Sleep concerns by age

PDSS for CDM patients

PSQ for CDM patients
Sleep and daytime sleepiness

Treatment options
1. Proper sleep hygiene, ENT and dental referral, medication review
2. Non-invasive ventilation
   • CPAP for obstructive sleep apnea
   • BiPAP for central apnea or hypoventilation
3. Medical management
   • Modafinil: mixed results  (Cochrane Review 2006)
   • Stimulants : methylphenidate  (vandermeche 1996, Puymirat 2012)
Motor Strength and Myotonia

- Myotonia rarely an issue in childhood
- Muscle weakness initially improves over first years of life in CDM
- Almost all children walk
- More typical pattern of muscle weakness in those with childhood DM1
- Hand and facial strength an issue for leisure, activities of daily living and eating
Myotonia:

- Rarely a problem early – i.e. before teen years, but after that can be an issue
- Mexiletine is used most often
- No quality study of drugs used in this situation (Cochrane review 2006)
- Phenytoin, carbamazepine, mexiletine have risk of cardiac arrhythmia - ECG pre/post
- Tricyclic antidepressants can be useful
Cardiac

- 80% of children with DM1 will have some ECG abnormality
- Rare before age 10
- Symptoms of fainting or palpitations common sign of heart problems
- Can be asymptomatic or the first sign of DM1
- An abnormal ECG is associated with cardiac death in adults (Groh 2008)
- Treatment: pacemakers
Medical Management and Monitoring

- **Gastro-Intestinal**
  - Chewing and swallow difficulties
    - Change in feeding techniques, g-tube
  - Pseudo-obstruction
    - Symptomatic treatment
  - Gastro-esophageal reflux
    - Antacid
  - Diarrhea
  - Constipation in 34%
    - Motility agent
    - PEG 3350
Medical Management and Monitoring

- Ophthalmology
  - Strabismus (cross-eyed) in 25-50% of children
  - Amblyopia (22%)
  - Cataracts very uncommon in pediatric practice
  - Need for corrective lenses (86%)
Medical Management and Monitoring

- **Orthopedic**
  - Scoliosis in 10%
    - Bracing and surgery
  - Contractures
    - Night splints, Ankle Foot Orthoses
  - Fragility fractures
    - Very uncommon, symptomatic management
  - Joint subluxation/dislocations
Other medical complications:
- Diabetes: not reported until adulthood
- Hypothyroidism: not reported until adulthood
- Bladder dysfunction
- Oral Health: more cavities and gingivitis than other children
- Potential treatment for DM1 with AON
  - Similar drug being used in babies with SMA
  - Data on safety in adult DM1 due soon

- What risk would one take for congenital DM1 child on a ventilator?
- Is that different for a child on feeding tube?
- What about the older child?
- Do you feel people with DM1 are more or less likely to take risks about treatment?
What is the definition of CDM?

Diagnosis

• Pregnancy Planning

• What is the definition of CDM?

ventilation

• Prognosis by duration?

Development

• Autistic features

Supportive management

• Heart Myotonia GI

Decision Making

Are you satisfied with the decision making process?
Are your preferences taken into account during decision making?
Are you satisfied with your decisions?
Are you compliant with your decisions?
Congenital DM1 is not well defined and so it is difficult to paint a uniform picture for parents.

Disorder of muscle immaturity.

Developmental and intellectual issues are key to advocate for the children.

Many other medical issues need to be monitored and discussed.

Are we supporting decisions properly?

Need to plan for clinical trials in pediatric patients.
Thank you

Nicolas Johnson, University of Utah
Pierre Jacob MD FRCPC, University of Ottawa
Victoria Siu MD FRCPC FCCMG, University of Western Ontario
Shannon Venance PhD MD FRCPC, University of Western Ontario
Melissa Mackay, Coordinator
Rhiannon Hicks, Coordinator

Colin Meyer-McAuley BSc
Sandra Magalhaes MSc
Patrick Prendergast MSc
Ada Ho BSc
Mahdavi Prasad, BSc

Supported through a generous donation to the Children’s Health Foundation and the Child Health Research Institute in London

William Singeris National Centre for Myotonic Dystrophy Research